



December 2004  Vol 8 No 6 Research
Effects of lornoxicam on the physiology of severe sepsis
Dilek Memis ¸1, Beyhan Karamanlıoğlu2, Alparslan Turan1, Onur Koyuncu1 and Zafer Pamukçu2
1Associate Professor, Department of Anaesthesiology and Reanimation, Medical Faculty, Trakya University, Edirne, Turkey
2Professor, Department of Anaesthesiology and Reanimation, Medical Faculty, Trakya University, Edirne, Turkey
Corresponding author: Dilek Memis ¸, dilmemis@mynet.com
Abstract
Introduction The purpose of the present study was to evaluate the effects of intravenous lornoxicam
on haemodynamic and biochemical parameters, serum cytokine levels and patient outcomes in severe
sepsis.
Methods A total of 40 patients with severe sepsis were included, and were randomly assigned (20 per
group) to receive either lornoxicam (8 mg administered intravenously every 12 hours for six doses) or
placebo. For both groups the following were recorded: haemodynamic parameters (heart rate, mean
arterial pressure), nasopharyngeal body temperature, arterial blood gas changes (pH, partial oxygen
tension, partial carbon dioxide tension), plasma cytokine levels (IL-1β, IL-2 receptor, IL-6, IL-8, tumour
necrosis factor-α), biochemical parameters (lactate, leucocytes, trombocytes, creatinine, total bilirubin,
serum glutamate oxalate transaminase), length of stay in the intensive care unit, duration of mechanical
ventilation and mortality. All measurements were obtained at baseline (before the start of the study) and
at 24, 48 and 72 hours from the start of lornoxicam/placebo administration.
Results No significant differences were found between the intravenous lornoxicam and placebo
groups in major cytokines, duration of ventilation and length of intensive care unit stay, and inspired
fractional oxygen/arterial oxygen tension ratio (P > 0.05).
Conclusion In these patients with severe sepsis, we found intravenous lornoxicam to exert no effect on
haemodynamic and biochemical parameters, cytokine levels, or patient outcomes. Because of the small
number of patients included in the study and the short period of observation, these findings require
confirmation by larger clinical trials of intravenous lornoxicam, administered in a dose titrated manner.
Keywords: biochemical parameters, cytokine levels, haemodynamic parameters, intensive care unit, lornoxicam, 
outcome, severe sepsis
Introduction
Sepsis is defined as the systemic response to infection [1,2].
The deleterious effects of bacterial invasion of body tissues
results from the combined actions of enzymes and toxins pro-
duced by the micro-organisms themselves, and the actions of
endogenous cells in response to the infectious process.
Despite advances in supportive care, mortality rates in patients
with severe sepsis continue to exceed 30%. During sepsis
vasoactive arachidonic acid metabolites of the cyclo-oxygen-
ase (COX) pathway are released. In particular, thromboxane
A2 and prostacyclin have been found to be elevated in sepsis
[3,4]. Thromboxane A2 has been associated with bronchocon-
striction, vasocontriction and platelet aggregation [3]. Prosta-
cyclin, the predominant eicosanoid generated by activated
endothelial cells, is a powerful vasodilator and antagonist of
thrombosis [3]. Prostaglandin (PG)E2  is among the most
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potent and inducible of the prostanoids that are produced in
states of inflammation. Specifically, there is evidence to sup-
port roles for PGE2 as a mediator of sepsis-induced immuno-
suppression, an inhibitor of proinflammatory cytokine
expression from monocytes, and an inducer of IL-10 produc-
tion [5-7]. Conversely, PGE2 has been shown to mediate det-
rimental effects in sepsis, including vasodilation and increased
vascular permeability [8]. In addition, its role as a mediator in
fever induction and augmentation of pain is well established
[9]. Several studies [10-12] conducted in endotoxin-chal-
lenged animals have found beneficial effects of nonselective
COX inhibitors. These beneficial effects were felt to be medi-
ated, in part, by mitigation of pathophysiological events in sep-
sis induced by PGs.
COX exists as two isoforms – COX-1 and COX-2. The former
is constitutively expressed, whereas COX-2 is expressed at
low levels in most normal resting cells. Marked upregulation of
COX-2 occurs in synoviocytes, macrophages and endothelial
cells during stress and in inflammatory conditions such as sep-
sis. COX-2 expression is induced by a number of cytokines,
including tumour necrosis factor (TNF) and IL-1, mitogens and
growth factors, lipopolysaccharide (LPS), and other inflamma-
tory stimuli [13]. Recent studies [14,15] provided evidence
suggesting that selective COX-2 inhibitors have significant
advantages over their nonselective counterparts. The specific
benefits of COX-2 inhibitors include decreased gastrointesti-
nal toxicity and bleeding [14,16].
As with other nonsteroidal anti-inflammatory drugs (NSAIDs),
lornoxicam inhibits PG synthesis via inhibition of COX, but it
does not inhibit 5-lipoxygenase. The ratio of inhibitory potency
of human COX-1 to COX-2 for lornoxicam is 0.6 [17]. Lornox-
icam was reported to be 100-fold more potent than tenoxicam
in inhibiting PGD2 formation in rat polymorphonuclear leuco-
cytes in vitro, and it was more active than indomethacin and
piroxicam in preventing arachidonic acid induced lethality in
mice in vivo [17]. Lornoxicam also inhibited the formation of
nitric oxide in RAW264.7 mouse macrophages stimulated
with endotoxin, indicating an effect on inducible nitric oxide
synthase [18]. It also exhibited marked inhibitory properties on
endotoxin-induced IL-6 formation in THP1 monocytes, with
less activity on TNF and IL-1β. It appears that lornoxicam, in
addition to markedly inhibiting COX and inducible nitric oxide
synthase, has a moderate effect on the formation of proinflam-
matory cytokines [19].
The purpose of the present study was to evaluate the effects
of intravenous lornoxicam on serum cytokine levels, haemody-
namic and biochemical parameters, and outcomes in humans
with severe sepsis.
Methods
Patient population and study design
The regional committee on medical research ethics approved
the study. Written informed consent was obtained, directly
from the patients wherever possible or from the next of kin.
Critically ill patients with bacteriologically documented infec-
tions were included in the study as soon as they met at least
two of the following criteria for sepsis, as defined by the Amer-
ican College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference Committee [2]: temperature
>38°C or <36°C; heart rate >90 beats/min; respiratory rate
>20 breaths/min or arterial carbon dioxide tension <32
mmHg; and leucocyte count >12 × 109 cells/l or <4 × 109
cells/l. In addition, at least one of following conditions was
required: hypoxaemia (arterial oxygen tension/fractional
inspired oxygen ratio <250); oliguria (urine output <0.5 ml/kg
body weight for 2 hours); lactic acidosis (lactate concentration
>2 mmol/l); thrombocytopaenia (platelet count <100 × 109/l);
and a recent change in mental status without sedation.
Patients who were younger than 18 years, had known or sus-
pected hypersensitivity to COX inhibitors, or had received a
COX inhibitor within 12 hours (or aspirin within 24 hours) were
enrolled in another experimental protocol (not part of the
present study), or were excluded if consent could not be
obtained. Also excluded were patients with known or sus-
pected brain death; those with advanced acute or chronic
renal or hepatic failure; those who had received potent immu-
nosuppressive drugs; those with gastrointestinal bleeding;
those who were pregnant; and those with a known irreversible
underlying disease, such as end-stage neoplasm.
The Acute Physiology and Chronic Health Evaluation
(APACHE) II score [20] and Sepsis-related (or Sequential)
Organ Failure Assessment (SOFA) score [21] (Table 1) were
employed to determine the initial severity of illness.
If required, patients underwent surgical procedures before the
start of the study. No invasive surgery was performed during
the 72-hour study period. All patients were ventilated in vol-
ume-controlled mode (Puritan Bennett 7200; Carlsbad, CA)
and received continuous analgesic sedation with midazolam
and fentanyl. Ventilator settings, level of positive end-expira-
tory pressure and fractional inspired oxygen were kept con-
stant during intravenous administration of lornoxicam or
placebo. Antibiotic treatment was adjusted according to the
results of bacteriological culture, such as blood culture or cul-
ture of samples taken from different body sites. In all partici-
pants fluid replacement was administered to maintain central
venous pressure between 4 and 8 mmHg. No inotropic agent
was administered during the study. Those patients who met
the criteria for severe sepsis presented above were enrolled in
the study within 8 hours of intensive care unit (ICU) admission.
Protocol
Randomization was done using a computer-steered permutedAvailable online http://ccforum.com/content/8/6/R474
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block design. The study was planned prospective, rand-
omized, double blind, and placebo controlled. In order to
perform the study in a double-blind manner, drug solution was
administered to all patients by a nurse who had no knowledge
of the study protocol, and follow up was done by an anaesthet-
ist who also had no knowledge of the study protocol. Twenty
patients received lornoxicam 8 mg (Xefo; Abdi Ýbrahim, Istan-
bul, Turkey), administered intravenously every 12 hours for a
total of six doses. In the placebo group, also including 20
patients, saline was administered using the same volume and
dosing regimen.
Measurements
All patients had arterial catheters placed (Abbott Transpac®
IV; Abbott, Sligo, Ireland) and central venous catheters placed
via subclavian (Certofix trio V 720 7F×8"; Braun, Melsungen,
Germany). Arterial blood samples were simultaneously with-
drawn for measurements of pH, partial oxygen tension, partial
carbon dioxide tension and arterial oxygen saturation (Medica
Easy BloodGas; Massachusetts, USA). Central venous pres-
sure, mean arterial pressure, heart rate and naso-opharyngeal
temperature were continuously monitored (Space Labs Inc.,
Redmond, WA, USA). All measurements were obtained at
baseline (before the start of the study) and again at 24, 48 and
72 hour after the start of infusion. Lactate, platelets, leuco-
cytes, bilirubin, alanine aminotransferase and creatinine were
determined at the same times (Vitalab Flexor, Dieren, The
Netherlands).
TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8 levels were meas-
ured at the same times. Venous blood was collected into a 10
ml sterile plain tube (without anticoagulant) before administra-
tion of any medications and stored at -20°C. Before assay, all
samples were thawed to room temperature and mixed by gen-
tle swirling or inversion. All sera were assayed on the same day
to avoid interassay variation. TNF-α, IL-1, IL-2 receptor, IL-6
and IL-8 levels were measured using a solid-phase, two-site
chemiluminescent enzyme immunometric assay method
(Immulite TNF-α, Immulite IL-1β, Immulite IL-2 receptor, IL-6
Immulite and IL-8 Immulite; EURO/DPC, Llanberis, UK). The
antibodies used in this procedure have no known cross-reac-
tivities with other cytokines. The intra-assay and interassay
coefficients of variation, respectively, for this procedure were
as follows: for IL-1β, 2.8–4.9% and 4.8–9.1%; for IL-2 recep-
tor, 2.9–3.7% and 6.1–8.1%; for IL-6, 3.6–6.2% and 5.4–
9.6%; for IL-8, 3.6–3.8% and 5.2–7.4%; and for TNF-α, 2.6–
3.6% and 4.0–6.5%. The lowest detectable limits of IL-1β, IL-
2 receptor, IL-6, IL-8 and TNF-α were 1.5 pg/ml, 5 U/ml, 5 pg/
ml, 2 pg/ml and 1.7 pg/ml, respectively.
The duration of mechanical ventilation was recorded. Survival
was defined as being alive at hospital discharge.
Statistical analysis
Repeated measures analysis of variance was used to evaluate
the differences between and within groups from baseline. In
the case of statistical significance, groups were tested by
independent sample t-test to determine which difference was
significant. Data are expressed as mean ± standard deviation.
P < 0.05 was considered statistically significant.
Results
Patient characteristics
Clinical and demographic characteristics of the patients are
listed in Table 2. Of the 40 patients included, 20 received
intravenous lornoxicam and 20 received placebo. Fifteen
patients had septic shock on admission (seven [35%] in the
lornoxicam group and eight [40%] in the placebo group) and
died while in the ICU. Baseline APACHE II scores (17.10 ±
3.58 and 18 ± 3.72 in the lornoxicam and placebo groups,
respectively) and SOFA scores (5.90 ± 1.72 and 6.20 ± 2.2)
were similar in the two groups (P > 0.05). SOFA scores at 24
Table 1
Sepsis-related (or Sequential) Organ Failure Assessment (SOFA) scores
Parameter SOFA score
01 2 3 4
Respiration (PaO2/FiO2 ratio) >400 ≤ 400 ≤ 300 ≤ 200 with respiratory support ≤ 100
Coagulation (platelets × 103/
mm3
>150 ≤ 150 ≤ 100 ≤ 50 ≤ 20
Liver (bilirubin [mg/dl (µmol/l)]) <1.2 (<20) 1.2–1.9 (20–32) 2.0–5.9 (33–101) 6.0–11.9 (102–204) >12.0 (>204)
Cardiovascular (hypotension) No hypotension MAP <70 mmHg Dopamine ≤ 5 or 
dobutamine at any dose
Dopamine>5 or adrenaline 
(epinephrine) ≤ 0.1 noradrenaline 
(norepinephrine) ≤ 0.1
Dopamine >15 or 
adrenaline >0.1 
noradrenaline >0.1
Central nervous system (GCS 
score)
15 19–14 10–12 6–9 <6
Renal (creatine [mg/dl] or urine 
output)
<1.2 1.2–1.9 2.0–3.4 3.5–4.9 or <500 ml/day >5 or <200 ml/day
FiO2, fractional inspired oxygen; GCS, Glasgow Coma Scale; MAP, mean arterial pressure;
PaO2, arterial oxygen tension.Critical Care    December 2004  Vol 8 No 6    Memis ¸ et al.
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hours (5.50 ± 1.52 and 6.1 ± 1.2 in the lornoxicam and pla-
cebo groups, respectively), 48 hours (5.60 ± 1.6 and 6.0 ±
1.3) and 72 hours (5.72 ± 1.4 and 6.1 ± 1.6) were also similar
(P > 0.05). Infection was documented in all patients.
Haemodynamic parameters and oxygen transport 
variables
There were no significant differences between groups with
respect to pH, partial oxygen tension, partial carbon dioxide
tension, arterial oxygen tension/inspired fractional oxygen ratio
and arterial oxygen saturation (P  > 0.05). No significant
changes in mean arterial pressure and heart rate were found
in either group (Table 3). There were no significant differences
between groups in biochemical parameters (Table 4; P  >
0.05).
Outcomes
Outcomes are listed in Table 2. In the ICU, the overall mortality
rates were 35% (seven patients out of 20) in the lornoxicam
group and 40% (eight patients out of 20) in the placebo group
(P > 0.05). All of those who died did so while they were being
mechanically ventilated. In the lornoxicam and placebo groups
the mean durations of ventilation were 6.1 ± 2.4 and 5.8 ± 3.1
days, respectively (P > 0.05). The length of ICU stay in lornox-
icam treated survivors was not significantly different from that
of placebo treated survivors (10.2 ± 7.1 versus 9.2 ± 8.4
days; P > 0.05).
Plasma cytokine levels
TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8 levels remained
unchanged during the study (Table 5).
Side effects
Intravenous lornoxicam was well tolerated by all patients, and
no side effects were noted during or after administration of
lornoxicam.
Discussion
Systemic inflammatory response leading to postoperative
organ dysfunction and sepsis remains a formidable clinical
challenge and carries a significant risk for mortality. Sepsis
and septic shock remain major causes of death in ICUs. A
number of studies have examined the role of nonselective
COX inhibitors both in animal models of sepsis and in patients
with sepsis syndrome. Several studies [10-12] demonstrated
beneficial effects of nonselective COX inhibition, predomi-
nantly in endotoxin-treated animals. However, subsequent
studies [22,23] examining the role played by NSAIDs, particu-
larly ibuprofen, in human sepsis trials have been disappointing.
The present study was therefore conducted to determine
whether COX inhibition is upregulated early after the onset of
severe sepsis, and if so whether COX inhibition prevents the
occurrence of septic shock.
The arachidonic acid pathway is highly activated in macro-
phages, monocytes and other inflammatory cells, resulting in
the formation of eicosonoids. PGs are involved in all phases of
the inflammatory process, including fever and pain reactions,
as well as in a large number of physiological functions, includ-
ing intestinal motility, platelet aggregation, vascular tone, renal
function and gastric secretion, among others. Two COX iso-
forms have been identified: COX-1 and COX-2. The former is
a constitutive enzyme that is expressed in many cells as a
Table 2
Demographic and clinical characteristics of lornoxicam treated and placebo patients
Characteristic Lornoxicam group (n = 20) Placebo group (n = 20)
Age (years [range]) 49 (19–87) 51 (20–89)





Urinary tract 1 1
APACHE II scorea 17.10 ± 3.58 18 ± 3.72
SOFA scorea 5.90 ± 1.72 6.20 ± 2.2
Duration of ventilationa 6.1 ± 2.4 5.8 ± 3.1
Length of staya 10.2 ± 7.1 9.2 ± 8.4
Mortality rate (%) 35 40
There were no significant differences between the groups. aValues are expressed as mean ± standard deviation. APACHE, Acute Physiology and 
Chronic Health Evaluation; SOFA, Sepsis-related (or Sequential) Organ Failure Assessment.Available online http://ccforum.com/content/8/6/R474
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house-keeping enzyme and stimulates homeostatic produc-
tion of PGs. COX-2 is an inducible form of the enzyme that is
expressed at the onset of inflammation by many cell types that
are involved in the inflammatory response. NSAIDs act mainly
through COX inhibitors, thus preventing the formation of proin-
flammatory prostanoids. Lornoxicam, a new member of the oxi-
cam class of NSAIDs, inhibits PG synthesis via inhibition of
COX, but it does not inhibit 5-lipoxygenase. Lornoxicam is at
least 10 times more potent as an anti-inflammatory agent than
piroxicam, and 12 times more potent as an analgesic than ten-
oxicam [17,19].
The primary pharmacological action of NSAIDs is, of course,
to decrease the formation of PGs and thromboxanes by inhib-
iting COX, a key enzyme in the biochemical pathway that leads
to formation of these potent mediators [24]. Accordingly,
products of the COX pathway, sometimes referred to as 'pros-
tanoids', have been implicated in the pathogenesis of the del-
eterious systemic consequences of serious infection and/or
endotoxaemia. In addition, the toxic effects of TNF (thought to
be one of the primary cytokines responsible for LPS-induced
lethality) can be ameliorated by treating mice or rats with
NSAIDs such as indomethacin or ibuprofen [25]. NSAIDs
have been shown to increase release cytokines (TNF, IL-6, or
IL-8) by stimulated mononuclear cells in vitro [26,27].
Complications of sepsis have been related to an intense host
response based on a delicate equilibrium between various
proinflammatory and anti-inflammatory mediators [28]. Over-
whelming production of proinflammatory cytokines, such as
TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8, may induce bio-
chemical and cellular alterations either directly or by orches-
trating secondary inflammatory pathways.
Reddyl and coworkers [5] evaluated the effect of pretreatment
with NS-398, a highly selective COX-2 inhibitor, on survival
Table 3
Haemodynamic, oxygen and temperature variables
Parameter Baseline Hours after the start of infusion
24 48 72
Heart rate (beats/min)
Lornoxicam 98 ± 24 99 ± 24 99 ± 22 96 ± 22
Placebo 95 ± 17 100 ± 23 98 ± 23 97 ± 22
Mean arterial pressure 
(mmHg)
Lornoxicam 91 ± 16 92 ± 13 89 ± 13 93 ± 13
Placebo 91 ± 18 93 ± 14 91 ± 12 89 ± 11
Arterial pH
Lornoxicam 7.34 ± 0.08 7.36 ± 0.07 7.33 ± 0.10 7.36 ± 0.06
Placebo 7.35 ± 0.07 7.37 ± 0.07 7.34 ± 0.07 7.37 ± 0.05
PaCO2 (torr)
Lornoxicam 34.8 ± 12.1 34.6 ± 11.8 35.00 ± 9.2 36.54 ± 11.1
Placebo 32.6 ± 10 33.5 ± 10.2 36.3 ± 10.13 34.33 ± 12
PaO2/FiO2 ratio (torr)
Lornoxicam 182 ± 68 186 ± 56 188 ± 64 189 ± 76
Placebo 184 ± 76 187 ± 45 181 ± 68 185 ± 68
SaO2 (%)
Lornoxicam 96.1 ± 3 96.1 ± 3.1 95.9 ± 3.8 95.9 ± 4.2
Placebo 96.9 ± 3.1 96.0 ± 3.2 96.0 ± 2.8 95.8 ± 3.9
Temperature (°C)
Lornoxicam 37.8 ± 0.75 37.2 ± 0.6 37.8 ± 0.5 37.9 ± 0.4
Placebo 37.6 ± 0.57 37.8 ± 0.4 37.6 ± 0.6 37.8 ± 0.5
No significant differences were found between groups. Data are expressed as mean ± standard deviation. FiO2, fractional oxygen tension; PaCO2, 
arterial carbon dioxide tension; PaO2, arterial oxygen tension; SaO2, arterial oxygen saturation.Critical Care    December 2004  Vol 8 No 6    Memis ¸ et al.
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and inflammatory mediator production in two models of sepsis
in mice (LPS challenge and peritonitis induced by caecal liga-
tion and puncture [CLP]). They found that selective inhibition
of COX-2 resulted in improvement in early survival in murine
endotoxaemia but not in a more physiologically relevant model
of abdominal sepsis (CLP). The early improvement in survival
in endotoxin-challenged animals was not attributable to
changes in inflammatory cytokine expression or organ-specific
neutrophil sequestration. Pretreatment with NS-398 failed to
improve long-term survival in either of the models studied,
although in the endotoxaemia model administration of the
COX-2 inhibitor had a modest salutary effect on early mortality.
In addition, although treatment with NS-398 blocked LPS-
induced increases in the circulating levels of immunoreactive
PGE2, injection of the COX-2 inhibitor did not modulate
plasma concentrations of TNF or the CXC chemokine KC.
Knoferl and coworkers [29] also evaluated the effect of pre-
treatment with NS-398, that trauma/haemorrhage results in
activation of Kupffer cells to release inflammatory mediators
and it leads to immunosuppression. In vitro production of IL-6
by Kupffer cells after CLP was significantly reduced by in vivo
NS-398 treatment. However, NS-398 had no effect on TNF-α
levels in vivo or in vitro. Strong and coworkers [12] showed
that administration of NS-398 for 24 hours after trauma
improved survival when mice were subjected to CLP and
puncture 7 days later. It is noteworthy that NS-398 exhibited
protective effects in two models of sepsis characterized by
infection in the setting of trauma-induced immunosuppression,
whereas the drug was largely ineffective when sepsis was
induced in immunocompetent animals. Dallal and coworkers
[30] demonstrated that T-cell suppression during neonatal
sepsis is accompanied by a decrease in IL-2 production. Such
suppression was ameliorated by COX-2 inhibitor, suggesting
a role for PGE2 in suppressed T-cell-mediated immune func-
tion in neonatal sepsis. Arons and colleagues [22] compared
the clinical and physiological characteristics of febrile septic
patients with those of hypothermic septic patients, and com-
pared plasma levels of cytokines TNF-α and IL-6 and throm-
boxane B2  and prostacyclin between hypothermic septic
patients and febrile patients. They administered ibuprofen but
found that this drug had no effect on cytokine levels.
Reddyl and coworkers [5] indicated that pharmacological inhi-
bition of COX-2 has only very modest effects on outcome in
experimental sepsis or endotoxaemia. Because these findings
are discrepant with respect to those obtained with isoform
nonselective agents, it is regrettable that those investigators
Table 4
Biochemical parameters
Parameter Baseline Hours after the start of infusion
24 48 72
Lactate (mg/dl)
Lornoxicam 25.2 ± 4.1 25.0 ± 3.9 25.9 ± 5.2 26.2 ± 3.7
Placebo 26.3 ± 3.8 26.7 ± 2.9 27.0 ± 3.1 26.9 ± 4.8
Platelets (×109/l)
Lornoxicam 192.9 ± 16.5 193.5 ± 15.0 178.1 ± 15.4 182.9 ± 15.6
Placebo 188.5 ± 14.4 190.8 ± 15.1 188.7 ± 13.3 190.5 ± 16.7
Leucocytes (×109/l)
Lornoxicam 14 ± 8.3 15.8 ± 8.3 16.0 ± 7.8 15.9 ± 6.2
Placebo 13.5 ± 6.6 14.7 ± 4.7 15.7 ± 6.7 14.8 ± 7.4
Bilirubin (mg/dl)
Lornoxicam 0.89 ± 0.38 0.90 ± 0.45 0.93 ± 0.33 0.90 ± 0.34
Placebo 0.90 ± 0.62 0.91 ± 0.38 0.92 ± 0.28 0.91 ± 0.36
Alanine aminotransferase (IU/l)
Lornoxicam 35.4 ± 5.5 36.0 ± 10.8 35.1 ± 8.6 36.7 ± 8.4
Placebo 35.4 ± 7.4 35.5 ± 5.2 36.2 ± 6.0 37.4 ± 4.9
Creatinine (mg/dl)
Lornoxicam 1.13 ± 0.96 1.15 ± 0.85 1.2 ± 0.3 1.28 ± 0.8
Placebo 1.01 ± 0.91 1.1 ± 0.65 1.08 ± 0.7 1.1 ± 0.8
No significant differences were found between groups. Data are expressed as mean ± standard deviation.Available online http://ccforum.com/content/8/6/R474
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did not include a 'positive control' arm in their studies to eval-
uate the effects of treatment with an agent such as indometh-
acin or ibuprofen in their laboratory's models of sepsis. In our
study we did not observe any significant changes in systemic
cytokine levels during NSAID administration in humans with
severe sepsis. Cytokine levels in plasma do not necessarily
reflect local synthesis of cytokines by cells. Many cells have
surface receptors for these cytokines with high binding prop-
erties, and target cells and soluble receptors trap cytokines.
Thus, cytokines released at the local level may remain unde-
tected in plasma. In the present study we found plasma
cytokine levels to remain unchanged over a period of 72 hours.
Wang and coworkers [31] conducted a study to determine
whether inhibition of PGI2 synthesis prevents the hyperdy-
namic response in early sepsis in animals. Those investigators
found that inhibition of PGI2 production did not prevent the
hyperdynamic and hypercardiovascular responses during
early sepsis; hence, mediators other than PGI2 appear to play
a major role in producing the hyperdynamic response under
such conditions. Fox and colleagues [32] postulated that the
attenuated pulmonary and systemic vascular contractility
observed in sepsis was secondary to the release of vasodilator
PGs. They used the COX inhibitor meclofenamate to inhibit
PG synthesis in a model of hyperdynamic sepsis, and found
that meclofenamate had no effect on either the pulmonary or
systemic response to phenylephrine infusion in septic animals.
However, Wanecek and coworkers [11] demonstrated that
endotoxin-induced pulmonary hypertension in the pig can be
prevented with a combination of the nonpeptide mixed
endothelin receptor antagonist bosentan and the COX inhibi-
tor diclofenac. They found that the combination of bosentan
and diclofenac induced systemic and pulmonary vasodilata-
tion. During endotoxin shock, this drug combination efficiently
counteracted pulmonary hypertension and improved cardiac
performance, and splenic and renal blood flows. These favour-
able circulatory effects might have resulted in a reduction in
both sympathetic nervous system activation and metabolic
acidosis. In the present study we found that lornoxicam had no
effect on the cardiovascular and pulmonary systems in severe
sepsis in humans, but our study was designed to assess the
effects of lornoxicam treatment given before septic shock but
after systemic inflammatory response syndrome. For this rea-
son we identified no serious cardiovascular and pulmonary
system problems in the patients studied.
Arons and coworkers [22] compared clinical and physiological
characteristics of febrile septic patients with those in hypo-
thermic septic patients, and compared plasma levels of
cytokines TNF-α and IL-6, and thomboxane B2 and prostacyc-
lin between hypothermic septic patients and febrile patients.
Those investigators found that ibuprofen treatment had a pos-
itive impact on vital signs, organ failure and mortality in hypo-
thermic septic patients, and concluded that ibuprofen could
Table 5
Cytokine levels
Cytokine Baseline Hours after the start of infusion
24 48 72
TNF-α (pg/ml)
Lornoxicam 25.7 ± 15 27.4 ± 16 26.68 ± 12.9 28.1 ± 16.8
Placebo 24.6 ± 18 25.4 ± 16.9 25.55 ± 11.8 26.3 ± 14.2
Il-1β (pg/ml)
Lornoxicam 6.4 ± 3.8 6.48 ± 6.07 6.21 ± 3.26 6.57 ± 1.8
Placebo 6.35 ± 1.4 6.2 ± 4.30 6.34 ± 4.2 6.19 ± 2.7
IL-2 receptor (U/ml)
Lornoxicam 1950 ± 1266 1890 ± 1150 1929 ± 1027 2050 ± 1100
Placebo 2270 ± 1110 2179 ± 1005 2300 ± 1190 2268 ± 1000
IL-6 (pg/ml)
Lornoxicam 100.6 ± 58 105.2 ± 54 108.5 ± 47 104.8 ± 38
Placebo 114.5 ± 385 115.6 ± 48 113.6 ± 51 116 ± 28
IL-8 (pg/ml)
Lornoxicam 171.50 ± 35 171.6 ± 19.3 172.1 ± 12.6 168.9 ± 11.3
Placebo 169.55 ± 27 168.3 ± 18.4 169.8 ± 18.2 171.0 ± 18.2
No significant differences were found between groups. Data are expressed as mean ± standard deviation. IL, interleukin; TNF, tumour necrosis 
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substantially decrease mortality in this selected group of sep-
tic patients. In our study we found that lornoxicam had no
effect on vital signs and mortality in patients with severe sep-
sis. The overall ICU mortality rate was 37.5% (15 patients out
of 40) in total, and these deaths were all attributable to septic
shock. However, all of the patients died after completion of the
study.
Lornoxicam has been shown to produce less gastric toxicity
than its nonselective counterparts. This may be especially
important in critically ill patients, who are at significantly
greater risk for developing gastric ulceration. In addition, the
lack of inhibitory effect on platelet function, which occurs with
the use of COX-2 selective compounds, may decrease the
incidence of bleeding complications [17,19]. In the present
study we did not identify any lornoxicam related adverse
effects.
In summary, we found that intravenous lornoxicam had no
effect on haemodynamic and biochemical parameters,
cytokine levels, or patient outcomes in severe sepsis. Selec-
tive inhibition of COX-2 in sepsis requires further study. How-
ever, the findings reported here, indicating that lornoxicam
lacks benefit in patients with severe sepsis, are disappointing.
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